working together - melanoma institute australia · 2016-08-05 · research highlights . 3 giving...

Working TogetherANNUAL REVIEW 2014–15

Melanoma Institute Australia – dedicated to preventing and curing melanoma through innovative, world-class research, treatment and education programs.

Annual Review 2014–15

Chairman’s Update 1Director’s Update 2Research Highlights 3Giving Together – Melanoma March 8Community Events Snapshot 9Working with the Community 11Patient Stories 132014–2015 Financial Breakdown 15Our Supporters 16

Front cover: Top: Dr James Wilmott researcher. Bottom: MIA patient Nick Hacket, with his wife Vivien.

Chairman’s Update Here at the Institute we appreciate that patients; their families and the community continue to play a significant role in helping us defeat melanoma. This year we not only celebrate our courageous patients in feature stories but also acknowledge their families, recognising the critical support they provide for relatives who are undergoing treatment.

We also recognise the tireless efforts of our fundraisers and volunteers, applauding their achievements in helping to raise awareness of melanoma through Watch Your Mate’s Back, and fundraise during community events and our biggest yearly campaign Melanoma March.

More than $630,000 raised during 2015, our most successful Melanoma March, will fund the Australian PDX Melanoma Project (AXMAP). This important project will enable Melanoma Institute Australia and melanoma research centres around the nation to work together to bank, distribute and analyse tissue samples. This research will be guided by our new understanding of melanoma’s genetic secrets, to drive the development of the next generation of new treatments.

We are once again grateful to receive a significant contribution towards our operating costs from the Poche family, who established our headquarters, The Poche Centre, with an initial $40 million donation. We are eternally thankful for their ongoing and generous support.

I thank our dedicated Board: Professor John Thompson AO, Associate Professor Jonathon Stretch AM, Garry Sladden and Jennifer Elliott for their continued commitment and work to equip and shape MIA for the future, building on our unique and respected history.

I also take this opportunity to thank our patrons, corporate partners and each and every individual fundraiser and volunteer for their ongoing support and contributions. Your generosity allows us to continue our mission to prevent and cure melanoma. By all working together, every day and into the future, we continue to make a difference to the lives of people who are battling melanoma.

Reg Richardson AM Chairman

It is with great pride that I once again reflect on the outstanding achievements of our talented and dedicated team at Melanoma Institute Australia. I continue to feel very privileged to work alongside some of the brightest people in the business, individuals who are leading research and pioneering clinical trials that you will be inspired to read about in the following pages.

Annual Review 2014–15 1

Director’s Update

Over the past year Melanoma Institute Australia (MIA) has continued to make significant advances in research which has driven critical developments in both medical and surgical treatments for melanoma patients. As the world’s largest melanoma research and treatment facility we continue to work in close partnership with our affiliates The University of Sydney, Westmead Institute for Medical Research, the Royal Prince Alfred Hospital and the Queensland Institute of Medical Research.

This year the family of MIA research teams was extended to include Macquarie University, where Professors Rick Kefford AM and Helen Rizos relocated during 2014. And our national leadership in melanoma research was recognised by renewed funding for 2016–2020 from the Australian Government through our third National Health and Medical Research Council (NHMRC) programme grant. This $14.6 million commitment is a significant endorsement of the important work we undertake at MIA.

Outstanding academic achievements have also continued. We have published 217 research articles, many in the world’s most respected medical journals, and our team has made scientific

presentations at 70 international conferences. We also remain committed to developing the melanoma specialists of the future, currently funding and training six Fellows in specialities including pathology, and medical and surgical oncology.

A steady stream of new patients has allowed us to further develop our Melanoma Research Database, which has undergone an important upgrade. We now have a detailed catalogue of over 39,600 patients. This database is driving ongoing work in many areas, filtering through to be published in journals and via presentations at conferences around the world.

In the following pages you will read about our contributions to several international studies and clinical trials which have improved outcomes for patients and are also helping pave the way for more tailored individual, ‘personalised’ medicine. Findings from studies on combination immunotherapies are taking us

to the next level of how we treat not just melanoma, but other types of cancer. We are confident that, by focusing on the science behind cancer, we can continue to improve therapies and prolong survival for patients.

I thank all our supporters for their continued efforts – from our individual donors to our corporate partners and patrons. Every dollar that you contribute helps us piece a little more of the challenging melanoma puzzle together. I also thank all the patients who allow us to use the data and tissue that we collect for research papers and who so willingly participate in clinical trials.

It’s an exciting time in the history of melanoma research and treatment. I thank our team for their incredible achievements, and believe that we can look forward to MIA breaking new ground and continuing to lead the way in melanoma research in the year ahead.

Professor John Thompson AO Executive Director

Director’s Update

“We are confident that, by focusing on the science behind cancer, we can continue to improve therapies and prolong survival for patients.”– Professor John Thompson AO

2 Annual Review 2014–15

Research HighlightsChanging the future together

Our dedicated researchers continue to make major advances and contribute to innovative medical care that is making a real difference to people living with melanoma. It has been a fruitful year, with new understanding of the way melanoma works and the continued impact of modern treatments that in the future might lead us to a cure.

Supporting global research Our Melanoma Genome Project team played a crucial role in a global study that discovered the most deadly form of skin cancer – cutaneous melanoma – has four distinct subtypes. The breakthrough helps pave the way for more tailored individual, ‘personalised’ medicine for melanoma patients. Samples from our BioSpecimen Bank made up close to a third of the global contributions to ‘The Cancer Genome Atlas’ (TCGA), a five year study of tumours from over 300 patients.

In addition, our Melanoma Genome Project, which is fully sequencing the DNA of 500 Australian patients, is nearing completion. It was endorsed by the International Cancer Genome Consortium early in 2015 and first results are soon to be published.

Advancing immunotherapy treatments Research from our clinical trials comparing immunotherapies in patients with advanced melanoma has contributed to a landmark worldwide study. We showed that the anti–PD-1 antibody pembrolizumab (Keytruda®) prolonged survival for advanced melanoma patients while also having less toxicity, compared with ipilimumab (Yervoy®) which had been the existing standard of care.

These world-first findings showed the anti-PD1 reduced the size of the tumours in patients with advanced melanoma in approximately 70% of cases, with a deep reduction in over 30% while also prolonging survival compared with ipilimumab.

The results, published in the world’s leading medical journal, the New England Journal of Medicine (NEJM), have been hailed as a critical development in the treatment of melanoma and are a milestone in terms of cancer treatment in general. Anti-PD1 treatments have now been listed on the Pharmaceutical Benefits Scheme (PBS) in Australia.

Targeted and neo-adjuvant therapyAmong several other milestones in clinical trials, published in the NEJM, MIA led studies to show that combined treatment with MEK inhibitors improves the outcome for people with BRAF-positive melanomas being treated with drugs that target the mutation.

6MIA FELLOWS

IN PATHOLOGY, MEDICAL AND

SURGICAL ONCOLOGY


Professors Rick Kefford AM and Helen Rizos, two of many in the team contributing greatly to MIA’s research. (Photo by Paul Wright.)

Our focus in the past year has been to start bringing these treatments further forward in the patient journey; so we have launched new trials to discover whether these effective drugs can improve the outcomes of surgery in people with tumours that may otherwise prove difficult to remove.

Moving data into the future Our Melanoma Research Database (MRD) has continued its growth in the last 12 months with contributions from our patients now making it the biggest catalogue of its kind in the world with over 39,600 records.

The MRD, which plays a key role in all our research work, has been capturing clinical information and histopathology data from melanoma patients since the 1960s. However, it has recently hit a significant milestone with a major upgrade and the initiation of the new MRD version 2.0 or MRD2 as it is known.

Our existing MRD was fast becoming out-dated as new therapies are now available that have significantly changed the way melanoma is treated. The updated data management system will more accurately reflect these changes, enabling us to cross-examine information and extract complex data. For the first time, details on patient bio-specimens will be held in the one place simplifying the processing and management of information. We will also be able to incorporate more detailed results for patients who are undergoing systemic therapies.

The tens of thousands of records held in MRD and its new big brother MRD2 are critical for melanoma research. The data are used in research into surgical and medical oncology, pathology, genetics, immunology, radiation therapy and diagnostic imaging and results are published in journals and via presentations at conferences around the world.

New technology supporting clinicians Earlier this year we launched our first smartphone app called ‘ClinTrial Refer Melanoma’ to help busy clinicians find clinical trials for melanoma patients. The app helps doctors match patients to available trials, avoiding the detailed research that would normally be required.

The app, which can be downloaded free from the App Store, includes up-to-date information on each trial which can be refined by location, trial status and sponsor. It is hoped the resource will not only prove a useful tool for clinicians, but will also increase participation in clinical trials by raising the profile of existing and new studies.


Advancing treatments together Building on our widely respected clinical research, which began in the late 1960s, our clinical trials team continues to push the boundaries of science. We are regularly testing new drug therapies to ensure melanoma patients are receiving the most promising treatments available.

This year, we have launched a world-first clinical trial to investigate treatment regimes that could offer new hope to patients with melanoma brain metastases.

The ABC Trial, supported by the Australia and New Zealand Melanoma Trials Group (ANZMTG) is comparing nivolumab (Opdivo®) and nivolumab in combination with ipilimumab (Yervoy®) in patients who have melanoma tumours that have metastasised to the brain.

We have recruited 37 patients from Sydney, Melbourne and Brisbane to take part in the trial. Patients from Adelaide are expected to join soon.

Clinical trials are an integral part of advancing new melanoma treatments, bridging laboratory discoveries with clinical medicine. MIA continues to be recognised as one of the most active melanoma research centres in Australasia.

Trials can be sponsored by pharmaceutical companies or are investigator-initiated. We have one of the largest investigator-driven clinical trial programmes in Australia, with approximately 40% of our trials being independent of industry.

Our work concentrates on surgical oncology, dermatology, radiotherapy and medical oncology using both immunotherapies and targeted therapies.

Dr Robyn Saw, who is contributing to the EAGLE FM project, and Associate Professor Georgina Long, who leads a number of our immunotherapy studies.


39,645MELANOMA PATIENTS IN THE MELANOMA RESEARCH DATABASE

Dr James Wilmott, a contributing researcher on our Melanoma Genome Project.

Contributing to global knowledge We had a strong presence again this year at the American Society of Clinical Oncology (ASCO) congress in Chicago. Overall our team made 22 presentations to the world’s largest oncology conference attended by 30,000 clinicians from around the globe.

Two large international trials presented during the event, to which MIA contributed, have shown that combinations of new melanoma drugs result in major improvements in disease control and patient survival compared to current therapies. These milestone trials bring encouraging news for patients with melanoma, but also have implications for all cancer patients.

One study (CheckMate 067) was the first Phase III trial to combine modern immunotherapy drugs in any cancer. It revealed improvements in both tumour response and patient survival with the combination of ipilimumab (Yervoy®) with the PD-1 antibody nivolumab (Opdivo®) compared to either therapy given alone.

This is not only a major advance for melanoma treatment, but also provides the impetus to attempt this approach in other cancer types and with other drug combinations.

Updated results were also presented from a targeted therapy trial (COMBI-D), where a BRAF inhibitor dabrafenib (Tafinlar®) was combined with a MEK inhibitor trametinib (Mekinist®) and compared to BRAF inhibitor treatment alone. Again, patients responded better and lived longer with better quality of life when given the combination treatment, cementing this as the new standard targeted therapy treatment for patients with BRAF-positive tumours.

Improving surgical treatment for patients An innovative surgical pilot study has been initiated this year. The Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) trial will help surgeons to develop comprehensive guidelines on the optimum operation for patients who have metastatic melanoma in their groin lymph nodes. This surgical research is an

Australian initiative and is coordinated by the Australia and New Zealand Melanoma Trials Group (ANZMTG). Twelve of the total 75 patients required have been recruited.

Results from this trial will feed into a planned larger Phase III international study involving melanoma units in Australia, the UK, Italy, Brazil, Slovenia and the Netherlands.

Thanks to ongoing and generous support from The Apex Melanoma Trust, Friends of The Mater and Cancer Council NSW, we continue to drive this important research, focusing on gaining evidence to improve the surgical treatment of melanoma patients into the future.


Giving Together – Melanoma March

Thousands of people across the country took action during Melanoma March 2015, making it the biggest and most successful year to date raising over $630,000 for research! The March saw exponential growth, adding additional sites around Australia bringing the total to 22 events nationally. Dedicated supporters helped us raise money while also increasing awareness and honouring the memory of those who have been lost to melanoma.

The money raised this year in collaboration with Melanoma Awareness Research Foundation (in South Australia) and melanomaWA (in Western Australia) will ultimately help researchers around the world develop avenues for future targeted therapy trials.

Since its inception in 2012, Melanoma March has continued to grow year-on-year. It is now the major annual fundraiser for national melanoma research.

Register or donate online at melanomamarch.org.au

and help us continue to fund life-saving melanoma research of national importance.

22MELANOMA

MARCH EVENTS IN 2015

MIA's Deputy Director Associate Professor Jonathan Stretch AM, chats with Melanoma March participants in Manly.


Community Events SnapshotRacing towards a cure Elise Beaton is a very determined woman; not only is she resolutely fighting advanced melanoma but in the last 12 months she’s also trained for and competed in the Melbourne Marathon, raising $18,000 for MIA research along the way!

The 33-year-old mother of two was encouraged to sign up for the marathon by her local running group ‘Running in the Burbs’, who also helped her fundraising efforts. “The amount of support I received from them not only got me to the start line of the marathon, but it helped pull me out of the unhealthy rut and mindset I was in and kicked me back into feeling normal again,” Elise said.

Elise’s husband Jason joined her to run the last 10 kilometres, in honour of their close friend Scott De Young who passed away from melanoma last year. He left behind a beautiful legacy in his wife Kim and three young children, “Just thinking of them helped us cross that finish line,” Elise added.

Elise took part in the 42 kilometre course around Melbourne together with her very supportive brother Adam. Elise said: “This is my opportunity to show what a recovering Stage IV patient can do with their lives, with a “never give up” attitude. This disease has taught us to live every moment like it’s your last and to enjoy every second... because in the blink of an eye, melanoma can very quickly strip you of that.”

Elise’s battle began after she discovered a lump in her groin in 2011. It was melanoma that had spread to her lymph nodes from a mole that had been removed from her foot when she was 19 years old. She was 11 weeks pregnant with her second child when she received her Stage III diagnosis.

“Two years after that, on a routine PET scan it was our worst nightmare. Results showed the melanoma had returned, this time back in my lymph nodes and on my lungs. At that point it was inoperable and I was diagnosed with Stage IV disease,” Elise recalls.

Elise has since begun targeted therapy. Her treatment is going well and currently she is cancer free.

Charlie’s Wish Golf Day After losing their much loved husband, father and grandfather to melanoma, the family of Charlie Hayes wanted to ensure his legacy lived on. Raising awareness and money to fund research for melanoma was a major priority for Charlie before he passed away.

Earlier this year, Charlie’s wife Barbara put out a call out to members of the close knit community of Old Bar organising ‘Charlie’s Wish Golf Day’ to help fund MIA’s research. Businesses large and small, sporting groups and individuals all gave generously to support the fundraising venture. The final event brought in just under $18,000. The money was a combination of sponsorships, donations, the sale of raffle tickets and green fees from the golf day.

However, the family’s efforts did not stop there – Barbara’s 11 year old grandson Riley had made a noteworthy contribution by holding his very own fundraiser – a fishing day for local children raising $300. Riley is aiming to hold another event later this year.

Elise Beaton (left) and friends at the completion of the Melbourne Marathon.

Barbara Hayes (right), Charlie's wife, with their grandson Riley on 'Charlie’s Wish Golf Day'.


Other donations in memoriam brought the family’s final fundraising tally to over $20,000!

Barbara said: “The response to our events was overwhelming and is testament to the high regard with which Charlie was held in his local community. We are proud as Charlie’s family that we have been able to fulfil his wish to raise money for research into this disease. The result was beyond our wildest expectations. We know this money helps MIA to continue its wonderful research to discover new treatments and hopefully a cure for this disease.”

Through the Looking GlassSince Emma Betts was first diagnosed with melanoma in 2013, she has been a dedicated advocate for melanoma research whilst also devoting a great deal of her time to raising over $71,000 for MIA research.

Emma’s February 2015 event, Through the Looking Glass, was a glamorous cocktail evening, which raised $36,000. The occasion included many of Emma’s favourite things, from stilt walkers to pavlova and champagne. Emma also held a raffle and live auction on the night which added to her already significant fundraising efforts.

Emma is well-known to many within the melanoma community. Her popular and inspiring blog Dear Melanoma documents her personal journey as a 24 year old living with Stage IV melanoma. Using her unique and honest writing style, Emma engages others who are going through similar experiences, as she focuses on creating an online forum where patients and families can share stories and support each other.

Emma Betts (left) and newsreader Alison Ariotti at Emma's 'Through the Looking Glass' event.


Learning togetherAfter several years in development, MIA has launched its first eBook Melanoma Essentials – A Concise Guide through the Apple iBooks Store. The new resource is for GPs and other medical, nursing and allied professionals who are not specialised in the treatment of melanoma, to help them effectively diagnose and manage cases.

In the coming months, the team will follow this publication with Melanoma: Principles & Practices, another eBook which details surgical and procedural atlases and interactive tools for specialist melanoma practitioners.

Supporting patients We have launched our new support packs, Your Guide to Early Melanoma for patients with Stage I or II melanoma. The guides have detailed information on the diagnosis and staging of melanoma, along with space for patients to keep personal details and records as they progress through their treatment.

The packs which have been supported by Neutrogena come in a handy carry bag with a free bottle of sunscreen.

If you or someone you know has been diagnosed with early stage melanoma, you can order a pack by contacting: [email protected].

We continue to provide monthly support groups where patients can share their melanoma journey with other individuals who have had similar experiences. These regular meetings are a great source of information and comfort to patients who can attend with their family and friends.

MIA currently holds monthly support groups in North Sydney and Wollongong and on the Central Coast. For more information visit: melanoma.org.au.

Educating the next generation The team at MIA is dedicated to treating and preventing melanoma and we are passionate about getting our important messages out to a crucial target audience – school students.

Visiting schools is an important part of our work because we know that 80-90% of melanoma cases are triggered by UV radiation, and the amount of cumulative sun exposure in the first 15 years of life is linked to an increased likelihood of adult skin cancers including melanoma.

The upside of these worrying statistics is that this life-threatening disease is also highly preventable.

This financial year we have visited over 30 schools in Wagga Wagga, Canberra, Port Macquarie, Illawarra, Northern Suburbs and Townsville, teaching pupils about the dangers of UV exposure and the consequences it can have in later life. Students learn what melanoma is and why it is so dangerous, facts and stats on skin cancer and very importantly, top tips on how to be sun-safe.

We are currently looking to expand our education programme, approaching principals and head teachers to ask if they would be interested in hosting a presentation.

School by school we are working to educate the next generation, teaching children how to be extra safe in the sun. Our messages are designed to have a tangible impact, changing behaviour and ultimately also helping us prevent the unnecessary death of one Australian every six hours.

If you have a teaching background and are interested in volunteering your time to support our work in schools, please contact: [email protected].

Working with the Community

Dr Alex Menzies consulting at MIA.


Watch Your Mate’s BackIn 2014 we launched our new awareness campaign Watch Your Mate’s Back (WYMB) which is designed to educate the community about melanoma by driving messages about prevention, early detection and action. We are encouraging Australians to be responsible for themselves and those around them when it comes to detecting melanoma.

The premise of the campaign is based on the fact that melanoma is often spotted by a spouse, friend or family member. It targets 15–39 year olds who are commonly outdoors, playing sports. WYMB aims to drive behaviour change in these young people, so sun safety and early detection become routine.

The unique website and posters encourage individuals to ‘watch their mate’s back’ by ensuring they apply sunscreen, check their skin for suspicious spots or moles and book themselves in for a professional skin check if they see any changes, while encouraging their mates to do the same.

WYMB was run in partnership with Surf Life Saving Australia, Rowing NSW, The Gap Health & Racquet Club and Lindfield Rugby Club, reaching an audience of over 100,000 people. The campaign is expanding this summer with a refreshed creative rolling out to new partners and a broader audience.

The Watch Your Mate’s Back launch campaign.

70INTERNATIONAL

SCIENTIFIC CONFERENCES


Patient StoriesNick’s story Nick Hacket is well known to many of our clinicians – he’s been one of our surgical patients for almost 16 years. Nick’s melanoma journey began in 1999 when he was first diagnosed after he had a suspect mole removed from his knee. Three years later Nick had lymph nodes removed after he developed lumps in his thigh. Since then he has undergone numerous and often complex surgeries to manage his disease.

One of his greatest challenges has been learning to swallow again after he had part of his larynx removed in 2006 when he spent six weeks in hospital. In comparison he says his recovery in 2014 following brain surgery for a metastatic tumour was straight forward – he was in and out of hospital and feeling well within a few days, straight back to his busy life!

Nick says his family has played a crucial role in helping him fight the battle against melanoma: “The support of my wife and family has helped me have the strength to continue to fight this disease for almost 16 years. Vivien and my children have been by my side, year in year out, every step of the way. In the good times and the bad, knowing I have the support of my family has made all the difference.”

Vivien, who has been married to Nick for 50 years, added: “We’ve all been there for Nick, whether it has been to attend appointments, or to encourage, listen and help as he’s needed us to. Our friends have also been wonderful supporting us as a family; this is something for which we are most grateful.”

“MIA is the best in the business. It’s inspiring to know that right here in our own backyard we have world-class experts who never give up and are continuing to improve the lives of melanoma patients every day.”

6,717 MELANOMA PATIENTS TREATED MIA patient Nick Hacket, with his wife Vivien.

– Nick Hacket


Grant’s story Grant Lawrence’s life changed dramatically in August 2014 when he was diagnosed with melanoma. The previous February a small pinkish lump appeared and was removed from the top of his shoulder which tests showed was not of concern. However, results from a biopsy in early August revealed melanoma.

Grant’s disease was at a stage that required extensive surgery which he underwent at MIA in conjunction with radiation therapy. Despite this intervention unfortunately the melanoma spread and he commenced immunotherapy soon after.

Grant’s mum and dad, Carolyn and Darryl, have been by his side throughout his diagnosis and treatment and they now accompany him on the 14 hour round road trip from their home in Nambucca Heads for his treatment at MIA every three weeks. The family’s commitment is paying off – after many months of therapy there is good news. Grant’s scans are showing the therapy has achieved remarkable results, “I am feeling really well. It was the best news that the treatment is doing what it is supposed to,” Grant said.

Grant’s parents are dedicated to getting their son well again. Carolyn said: “It doesn’t matter if your child is 8, 18 or 28 you just want them to be happy and healthy. We know Grant is getting world class care from the medical teams at MIA. Our job as a family is to be there for Grant, together with the professionals, giving him additional emotional strength to fight the disease. Travelling a 14 hour round trip every three weeks is a small price to pay to be able to access the excellent quality and care provided by the doctors and support staff at MIA and The Mater Hospital. They are doing an incredible job, and all the hard work. The trip is easy compared to the challenges Grant is facing.”

Grant added, “Mum and Dad have been amazing. My brother and sister in law also flew down from Brisbane when I first started my treatment at MIA. They, along with my now one year old identical twin nephews have been by my side. I can’t tell you the difference it makes to have your family supporting you when you’re going through something like this.”

“My heroes are MIA’s doctors, nurses and researchers who are devoting their lives to treating and curing melanoma.”

28 year old MIA patient Grant Lawrence (centre), with his mum and dad, Carolyn and Darryl.

– Grant Lawrence


Sundry income (1%)

Donations (44%)

Investment income (10%)

Rental income (9%)

Research income (35%)

2014–2015 Financial BreakdownTotal income – $10,614,000

Total expenditure – $8,662,000 Investment fees (1%)

Depreciation expense (2%)

Building (8%)

Fundraising (11%)

Administration (18%)

Research expense (60%)

Please note, due to rounding, percentages may not add up to 100%.


Our Supporters We are tremendously grateful for the continuing support of the many and varied individuals and organisations who fund our research through donations, bequests, community fundraising and grants. Below we recognise some of those who have provided critical funding to support our ongoing research work.

Principal BenefactorGreg Poche AO and Kay Van Norton Poche

Major BenefactorMelanoma FoundationPeter and Sally Doherty (CP2)The Cameron Family

Governors Apex FoundationClearbridge FoundationNeville & Robyn NewtonPerpetual FoundationPetre FoundationReg Richardson AM & Sally RichardsonSkipper Jacobs Charitable TrustThe Macintosh Foundation

Companions Ann and Jerry Ellis AOBradley HuntEmma Betts – Community FundraiseriNova PharmaceuticalsJohnson & Johnson Pacific Pty LtdMichael AlscherSteve & Michelle BennettTAL Services LtdThe Estate of The Late Zara SplayfordToyota Australia

FellowsBernard BersonBob Mac SmithBrett HinesCoca-Cola Australia FoundationDave CosentinoEstate of The Late Ann Margaret CampbellGai & Tony WalesGary JohnstonGlenn & Caroline Crane Jo PhillipsJulie & Don PriestKathy White – Geoff White InvestmentsMacquarie Group FoundationManildra FoundationMark & Toni HeathNicolette LewisPeter HemmingPeter RockeyPlayfair Family & FriendsRobert Albert AOSunspots Melanoma CommitteeSusan Maple-BrownThe Late Pauline Cronly-DillonThe Mather Family – Balmoral Beach Club

FriendsAdam Thillart and Michael Hutchinson – Community FundraisersAdele Veivers – Community FundraiserAndrew Morbey – Community FundraiserAustralian Communities FoundationCancer Institute NSWDavid & Caroline LewisDick and Pip Smith FoundationDick Smith Food FoundationElise Beaton – Community FundraiserGlobal CreaturesNathan Pegler – Illawarra Melanoma Support GroupJoanna Dolan – Donate4KateJocelyn LloydJoe CollinsJonathan Stretch AMKaren Pierson – Community FundraiserKarlee Adams FoundationKeith & Maureen KerridgeKerry BraslinKerry MoranKerry WeirLeonie EnglefieldLin Huddleston Charitable Foundation

Thanks to all of our dedicated Melanoma March committees across Australia for their continued efforts to raise money for national melanoma research while also helping spread awareness about the most serious form of skin cancer.

Committee Leaders 2015 James Economides – Manly, NSW Paula Jackson – Bonny Hills, NSW Amanda Lucci & Nathan Jones – Melbourne, VIC Veronica Manock – Bathurst, NSW Kerry Weir, Nev Weir & Kate Davis-Steel – Brisbane, QLD

Nicole Miller & Hayley Van Elst – Gosford, NSW melanomaWA (Clinton Heal) – Karratha, Perth, Bunbury, Rockingham, Busselton, WAKaren Ryan & Tennille Shelley – Wollongong, NSW Violets and Lace Committee – Townsville, QLD

Australian Melanoma Research Foundation (Rachael Sporn) – Adelaide, SA Tony Van de Wakker & The Strand Coolangatta – Coolangatta, QLD Leonie Warburton & Hayley Chalkley – Darwin, NTJoy Leishman – Bribie Island, QLD Lyn Rowe & Judy Middlebrook – Canberra, ACT

Melanoma March supporting national research


BioSpecimen Bank Manager Valerie Jakrot.

4,062MADE A DONATION TO MIA RESEARCH

Lucinda and Anthony Ryan – Community FundraisersMusicians 4 Melanoma and Other CancersNigel MastersRobert FergusonVinta Group Pty LtdViolets & LaceWilliam CantYvonne Schofield

Jay Allen & Jennifer Skuja – Picton, NSW Cindee Hammond – Taree, NSW Kath Priest & Rachael Viski – Wagga Wagga, NSW Nicole Brown – Cairns, QLD

melanoma.org.au

The Poche Centre40 Rocklands RoadWollstonecraft NSW 2065Australia

p. +61 2 9911 7200 e. [email protected]. 35 123 321 148CFN. 20341

working together - melanoma institute australia · 2016-08-05 · research highlights . 3 giving...

Documents